Granules India Ltd.
Snapshot View

379.35 +7.90 ▲2.1%

30 July 2021, 04:00:00 P.M.
Volume: 408,908

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.granulesindia.com
Financial Indicators
Market Cap 9,395.54 Cr.
Earnings per share (EPS) 22.54 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 16.83 Trailing Twelve Months Ending 2021-06
Industry PE 34.39 Trailing Twelve Months Ending 2021-06
Book Value / Share 91.70 Trailing Twelve Months Ending 2021-06
Price to Book Value 4.14 Calculated using Price: 379.35
Dividend Yield 0.40 Period Ending 2021-03
No. of Shares Subscribed 24.77 Cr. 247,674,796 Shares
FaceValue 1
Company Profile

Granules India Limited is a large-scale vertically integrated Company founded in 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). The Company over the years has created a strong presence in ‘the first line of defence’ products such as Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin.

The company’s product-focused, vertically integrated business model has created a leadership position in several generic drugs. It has a strong presence in ‘first line of defence’ products, including Paracetamol, Ibuprofen, Guaifenesin and Metformin. It exports nearly 60% of its revenue to the US and Europe. Its key customers include some of the leading generic, as well as, branded pharmaceutical companies. Its integrated model for manufacturing APIs, PFIs and Finished Dosages enables it to provide products across the value chain and enhances its competitiveness. It has emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Business area of the company

Granules India is one of the vertically integrated, high-growth pharmaceutical manufacturing company in India today. Based out of Hyderabad, India, it is into manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediaries (PFIs) and Finished Dosages (FDs).

Products of the company

  • Active Pharmaceutical Ingredients
  • Pharmaceutical Formulation Intermediates
  • Finished Dosages
  • Speciality Products

Milestones

  • 1991: Trading of APIs
  • 1994: Production of various APIs
  • 1995: Venture into the manufacture of DC Paracetemol (PFI)
  • 1996: Targeting of OTC market in the US for Paracetemol PFI.
  • 1998: Expansion of PFI capacity.
  • 2000: Obtaining US FDA approval for PFI and other APIs.
  • 2001: Development of new PFIs such as Guaifenesin, Metformin and Ibuprofen etc.
  • 2002: Filing of new DMFs of the above PFIs and moving up of value chain in OTC products.
  • 2003: Setting up of the world's single largest PFI facility with a capacity of 7,200 TPA.
  • 2004: The only company in the world to manufacture combination PFIs on a commercial scale using different basic APIs with other excipients.
  • 2004: Addition of a Tableting facility with a capacity of one billion pieces per annum
  • 2005: Started construction of the Tableting facility with a capacity of 12 billion tablets.
  • 2006: Major expansion of Paracetamol facility, from a capacity of 3600 MT to 12000MT per annum
  • 2010: Granuels India Receives U.S. FDA Approval for its Metformin ANDA.
  • 2011: Granules established Granules-OmniChem, a JV with Ajinomoto OmniChem. The business focuses on the CRAMS space
  • 2012: Granules India Awarded India’s Most Admired Company in Exports & India’s Most Admired Company in Bulk Drugs.
  • 2012: Granules India Awarded Outstanding Exports - Formulations Award 2011-12 by Pharmexcil.
  • 2013: Granules acquired Auctus Pharma.
  • 2016: Wholly owned subsidiary Granules Pharmaceticals Inc (GPI) enters into agreement to acquire 12.5% stake in US based USPharma.
  • 2017: Granules India Limited featured in the list at 60th place in Fortune India's 2017 list of The Next 500 Companies.
  • 2018-19: Granules Pharmaceuticals Inc. launched generic Methylergonovine tablets (Methergine) in partnership with Hikma Pharmaceuticals Plc.
  • 2018-19: Granules Pharmaceuticals Inc. successfully launched Metformin XR and Methocarbamol under its own label.
  • 2020: Granules India gets nod to set up subsidiary in Hyderabad.
  • 2020: Granules India gets marketing approval from US FDA for Potassium Chloride Extended Release Tablets.
  • 2021: USFDA approves ANDA filed by Granules India’s arm for Potassium Chloride Oral Solution.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.13%
1 Week
-0.04%
1 Month
+14.09%
3 Month
+13.75%
6 Month
+12.52%
1 Year
+36.38%
2 Year
+319.17%
5 Year
+166.49%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 12.67 24.20 23.29 23.53 18.23 10.60 13.32 18.54 27.64
Return on Capital Employed (%) 12.95 19.90 18.81 20.16 16.57 11.09 12.71 17.22 25.38
Return on Assets (%) 5.19 8.98 8.28 9.03 8.12 5.13 6.64 9.99 15.84

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 275 356 431 662 904 1,304 1,529 1,844 2,173
Non Curr. Liab. 202 344 357 247 188 488 553 486 366
Curr. Liab. 206 293 415 655 787 878 896 893 1,173
Minority Int.
Equity & Liab. 683 992 1,203 1,563 1,879 2,670 2,979 3,223 3,713
Non Curr. Assets 389 612 700 745 1,051 1,484 1,696 1,594 1,716
Curr. Assets 289 377 500 818 828 1,187 1,282 1,629 1,997
Misc. Exp. not W/O 5 4 3
Total Assets 683 992 1,203 1,563 1,879 2,670 2,979 3,223 3,713

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 764 1,096 1,294 1,357 1,411 1,685 2,279 2,599 3,238
Other Income 2 4 4 6 10 11 27 37 27
Total Income 766 1,100 1,297 1,363 1,420 1,695 2,306 2,635 3,264
Total Expenditure -679 -938 -1,084 -1,081 -1,112 -1,406 -1,895 -2,073 -2,382
PBIDT 87 163 213 282 309 289 411 562 882
Interest -18 -20 -32 -37 -32 -33 -28 -27 -26
Depreciation -23 -30 -53 -58 -72 -76 -105 -137 -151
Taxation -14 -37 -37 -61 -65 -63 -89 -116 -155
Exceptional Items 28
PAT 33 75 91 125 140 117 188 310 549

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 91 108 150 151 188 -1 262 476 432
Cash Fr. Inv. -128 -255 -146 -162 -326 -462 -270 -161 -277
Cash Fr. Finan. 46 147 19 86 56 529 -17 -213 -299
Net Change 10 0 24 75 -82 66 -25 103 -144
Cash & Cash Eqvt 42 42 65 130 42 108 83 186 42

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 42.90 42.90 42.90 42.86 42.13 42.04 42.04 42.04 42.04
Public 57.10 57.10 57.10 57.14 57.87 57.96 57.96 57.96 57.96
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 43.40 36.99 30.29 37.62 8.64 8.64 8.64 8.64 6.92

Announcements View Details

Fri, 30 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Tue, 27 Jul 2021
Un-Audited Financial Results For The Quarter Ended June 30 2021.
Un-audited financial results for the quarter ended June 30 2021.
Tue, 27 Jul 2021
Outcome Of Board Meeting Dated July 27 2021.
Outcome of Board Meeting Dated July 27 2021.

Technical Scans View Details

Thu, 29 Jul 2021
Both SRS And ARS Below Zero Both SRS And ARS Below Zero
NR 4 NR 4
NR 7 NR 7
Wed, 28 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 774.00 +10.1%
Divi's Laboratories Ltd. 128,656.69 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,712.70 +0.9%
Cipla Ltd. 71,170.06 920.30 +4.3%
Cadila Healthcare Ltd. 58,547.84 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,214.94 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 29.59 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 3.88 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%